With a new licensing agreement, makers of generic drugs can now develop and sell a pediatric HIV drug to low- and middle-income countries. We reached out to the Medicines Patent Pool to give you the inside track into what this deal means for the global HIV and AIDS fight.
Sign in or join Devex to read the rest
Not only will you get to finish this article, you will also unlock access to community content from our global team of journalists covering the latest global health, humanitarian aid and international development news. And it's totally free.
